{"log_id": 1460613229609262496, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0, "average": 0.969366, "min": 0.969366}, "location": {"width": 27, "top": 70, "height": 27, "left": 1454}, "words": "文"}, {"probability": {"variance": 0.020734, "average": 0.919697, "min": 0.529269}, "location": {"width": 925, "top": 137, "height": 80, "left": 342}, "words": "现肌痛,关节痛等。绝大多数不良反应经对症处理后可以好转,不影响继续月"}, {"probability": {"variance": 0.0198, "average": 0.915534, "min": 0.445299}, "location": {"width": 567, "top": 208, "height": 64, "left": 345}, "words": "药,极个别病倒上述症状持续存在,应考虑停药"}, {"probability": {"variance": 0.028395, "average": 0.904779, "min": 0.452433}, "location": {"width": 875, "top": 246, "height": 77, "left": 400}, "words": "2.过敏反应:极少数患名用药后可能出现皮线荨麻疹等过敏反应,包括"}, {"probability": {"variance": 0.021453, "average": 0.92006, "min": 0.390026}, "location": {"width": 928, "top": 301, "height": 77, "left": 347}, "words": "过敏性体克。因此,初次使用本品或重使用本品时,建议先使月少量,确定"}, {"probability": {"variance": 0.015482, "average": 0.926588, "min": 0.544712}, "location": {"width": 777, "top": 361, "height": 70, "left": 352}, "words": "无异常反应后,再注射全量,如发现异常,应立即停药并善处理"}, {"probability": {"variance": 0.013132, "average": 0.93928, "min": 0.460791}, "location": {"width": 875, "top": 406, "height": 75, "left": 402}, "words": "3.心脑血管系统:血生升高、原有的高血压恶化和因高血压脑病而有头"}, {"probability": {"variance": 0.014811, "average": 0.945989, "min": 0.431206}, "location": {"width": 930, "top": 459, "height": 80, "left": 352}, "words": "意识障碍、痉挛发生,甚至可引起脑出血。因在红细生成素注射液治疗期"}, {"probability": {"variance": 0.027919, "average": 0.911537, "min": 0.354239}, "location": {"width": 884, "top": 516, "height": 75, "left": 354}, "words": "间应注意并定期观察血压变化,必要时应量或停药,并调整降压药的剂量"}, {"probability": {"variance": 0.032632, "average": 0.873888, "min": 0.469355}, "location": {"width": 871, "top": 569, "height": 73, "left": 409}, "words": "4,血液东统随着红细胞压积增高,血液粘皮可显增高,因出应注意"}, {"probability": {"variance": 0.00207, "average": 0.972694, "min": 0.882083}, "location": {"width": 141, "top": 658, "height": 32, "left": 358}, "words": "止血栓形成"}, {"probability": {"variance": 0.007223, "average": 0.942995, "min": 0.670959}, "location": {"width": 368, "top": 697, "height": 41, "left": 411}, "words": "5.肝脏:有COT、GFT的上升"}, {"probability": {"variance": 0.006289, "average": 0.960039, "min": 0.63872}, "location": {"width": 706, "top": 731, "height": 66, "left": 409}, "words": "6.胃肠:有时会有恶心呕,食欲不振、腹等情况发生"}, {"probability": {"variance": 6.8e-05, "average": 0.991926, "min": 0.980238}, "location": {"width": 93, "top": 813, "height": 34, "left": 370}, "words": "禁忌】"}, {"probability": {"variance": 0.018315, "average": 0.924247, "min": 0.581656}, "location": {"width": 331, "top": 855, "height": 50, "left": 416}, "words": "1.末控制的重度高血压患者"}, {"probability": {"variance": 0.027405, "average": 0.887258, "min": 0.51532}, "location": {"width": 512, "top": 898, "height": 61, "left": 418}, "words": "2.对本制剂或其它红细胞生成崇剂过敏者"}, {"probability": {"variance": 0.003571, "average": 0.965508, "min": 0.777016}, "location": {"width": 489, "top": 953, "height": 57, "left": 418}, "words": "3会并感染者,宜控制感染后再使用本品"}, {"probability": {"variance": 0.014329, "average": 0.925047, "min": 0.663375}, "location": {"width": 146, "top": 1024, "height": 34, "left": 379}, "words": "【注意事项】"}, {"probability": {"variance": 0.005864, "average": 0.908871, "min": 0.832177}, "location": {"width": 116, "top": 1074, "height": 38, "left": 409}, "words": "特别注意"}, {"probability": {"variance": 0.019341, "average": 0.898972, "min": 0.56671}, "location": {"width": 852, "top": 1092, "height": 75, "left": 450}, "words": "文航报道,在慢性肾功能衰竭患者的1床研究中,红细生成素类药"}, {"probability": {"variance": 0.011575, "average": 0.930627, "min": 0.607308}, "location": {"width": 932, "top": 1143, "height": 82, "left": 370}, "words": "品(ESAs)给药后,当血红蛋白水平三13gic1时,患者发生死亡、严重心血管"}, {"probability": {"variance": 0.000266, "average": 0.982459, "min": 0.95887}, "location": {"width": 274, "top": 1230, "height": 43, "left": 374}, "words": "事件和卒中的风险增加"}, {"probability": {"variance": 0.023938, "average": 0.918251, "min": 0.363096}, "location": {"width": 877, "top": 1250, "height": 77, "left": 429}, "words": "采用个性化给药方案,以达到并保持老止红蛋白水平在10~-12g/ll范围"}, {"probability": {"variance": 0.036894, "average": 0.846268, "min": 0.43688}, "location": {"width": 928, "top": 1303, "height": 77, "left": 377}, "words": "内、临床研究中,对于血红蛋白水平≥13g/4d的慢性肾功能衰竭患者给予ESs"}, {"probability": {"variance": 0.022353, "average": 0.913956, "min": 0.44846}, "location": {"width": 935, "top": 1353, "height": 80, "left": 377}, "words": "治疗时:其发生死亡、严重心血管事件和中的风险较高:对FSA5治疗应答不"}, {"probability": {"variance": 0.015723, "average": 0.94332, "min": 0.41402}, "location": {"width": 932, "top": 1406, "height": 82, "left": 379}, "words": "充分的慢性肾功能衰患者发生心血管事件和死亡的危险比其他患高,在对"}, {"probability": {"variance": 0.021172, "average": 0.929235, "min": 0.413383}, "location": {"width": 935, "top": 1458, "height": 82, "left": 379}, "words": "癌症患者进行的临床对照研究中,FSAs可增加死亡和严重心血管件发生的风"}, {"probability": {"variance": 0.02577, "average": 0.883673, "min": 0.452403}, "location": {"width": 935, "top": 1511, "height": 82, "left": 379}, "words": "险。这些事件包心梗、卒中,充自性心力竭、血液透析血管通路血栓"}, {"probability": {"variance": 0.043047, "average": 0.788483, "min": 0.408242}, "location": {"width": 781, "top": 1572, "height": 73, "left": 388}, "words": "这些风险的产生可能与红白水两同内超过11"}, {"probability": {"variance": 0.027281, "average": 0.888458, "min": 0.364743}, "location": {"width": 850, "top": 1614, "height": 82, "left": 470}, "words": "文猷报道,对乳癌、非小细泡肺癌、头颈,淋巴癌和宫颈患者"}, {"probability": {"variance": 0.030159, "average": 0.902204, "min": 0.38159}, "location": {"width": 935, "top": 1669, "height": 80, "left": 388}, "words": "进行临床研究中,ESAS缩短患者的生车期和,成增加肿瘤展堂复发的风"}, {"probability": {"variance": 0.043521, "average": 0.704379, "min": 0.495761}, "location": {"width": 70, "top": 1895, "height": 36, "left": 1312}, "words": "技犬"}], "language": 3}